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Background: H5N1 highly pathogenic avian influenza virus (HPAIV) is continuously circulating in many Asian
countries and threatening poultry industry and human population. Vaccination is the best strategy to control H5N1
HPAIV infection in poultry and transmission to human population. The aim of this study is to identify new
temperature-sensitive (ts) mutations for developing recombinant avian live attenuated H5N1 influenza vaccine.
Findings: A “6 + 2” recombinant virus C4/W1 that contained NA gene and modified HA gene from virus A/chicken/
Hubei/327/2004 (H5N1) (C4), and six internal genes from virus A/duck/Hubei/W1/2004 (H9N2) (W1) was generated
using reverse genetics and subsequently passaged in chicken eggs at progressively lower temperatures (32°C, 28°C
and 25°C). The resulting virus acquired ts phenotype and one of its amino acid mutations, PA (F35S), was identified
as ts mutation. Furthermore, when used as live attenuated vaccine, the recombinant virus with this ts mutation PA
(F35S) provided efficient protection for chickens against H5N1 HPAIV infection.
Conclusions: These findings highlight the potential of the new ts mutation PA (F35S) in developing recombinant
avian live attenuated H5N1 influenza vaccine.
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H5N1 HPAIV is continuously circulating in many Asian
countries and threatening poultry industry and human
population. An effective vaccine to protect poultry from
infections of H5N1 HPAIV is needed not only to reduce
economic losses in the poultry industry, but also to
minimize virus transmission from infected poultry to
humans [1].
Live attenuated influenza vaccine (LAIV) with needle-
free intranasal administration and cross-protection is at-
tractive in controlling pandemic influenza. Recombinant
influenza virus with C-terminal truncated NS1, deficient
NA, cleavage-site modified HA or cytoplasmatic-tail
deleted M2 has been reported as LAIV [2-5]. Besides
these, low-temperature passage has been commonly used
to acquire LAIV with ts phenotype [6-8]. The ts muta-
tions were identified in internal genes of the LAIVs [9],* Correspondence: jinmeilin@mail.hzau.edu.cn
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reproduction in any medium, provided the orand some LAIVs were subsequently used as master
donor virus (MDV) to generate new LAIVs by reassort-
ment with two surface glycoprotein genes from currently
epidemic strains [10-13].
LAIV has been widely used in humans, while rare
LAIV was reported to be used for poultry. Lee et al.
developed an avian H9N2 LAIV by successively passaged
a wild-type H9N2 influenza virus A/Chicken/Korea/S1/
03 in embryonated chicken eggs at progressively lower
temperatures [7]. Although the ts mutations of the avian
H9N2 LAIV were not identified, some of the amino acid
mutations (PB2N265S, PB1K391E/E581G/A661T and NPD34G)
were similar to the ts mutations of the MDV A/Ann
Arbor/6/60 (H2N2). However, transferring these ts
mutations (PB2N265S, PB1K391E/E581G/A661T and NPD34G)
into the corresponding internal genes of an avian H9N2
influenza virus A/Guinea Fowl/Hong Kong/WF10/99
could not sufficiently result in an avian live attenuated
H9N2 influenza backbone, further introduction of an
HA tag into PB1 gene was needed [14]. This strategy of
generating avian live attenuated H9N2 influenza backboneLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be identified.
Therefore, the aim of this study was to acquire new and
simple ts mutations within an avian H9N2 influenza back-
bone for developing recombinant avian live attenuated
H5N1 influenza vaccine. All experiments with H5N1
HPAIV were performed in ABSL-3 containment facility.
We initially generated a “6+ 2” recombinant virus C4/W1
that contained NA gene and modified HA gene (cleavage
site was changed from PQRERRRKKR#G to low patho-
genic characteristic PQIETR#G) [15] from H5N1 influenza
virus A/Chicken/Hubei/327/2004 (C4) [16], and six in-
ternal genes from H9N2 influenza virus A/Duck/Hubei/
W1/2004 (W1) [17]. Recombinant virus C4/W1 was then
serially passaged in chicken eggs for 10 times at 32°C and
28°C respectively and 15 times at 25°C [7,8].
The ts phenotype of this low-temperature passaged
virus was evaluated. Six 10-day-old specific-pathogen-
free (SPF) chicken eggs were inoculated with 103 EID50
of the low-temperature passaged virus (0.2 ml/egg) and
incubated at 37°C or 41°C for 48 hours, the parent virus
C4/W1 was used as comparison. Allantoic fluids were
collected and viral titers were determined by 50% egg in-
fectious dose (EID50) at 37°C. Virus could be considered
ts if it displayed 100-fold or greater reduction in viral
titers at 41°C compared with that observed at 37°C. As
shown in Figure 1, virus C4/W1 and the low-temperature
passaged virus grew efficiently at 37°C (9.3 or 9.1 log10
EID50/ml, respectively). Nevertheless, at 41°C, the virus
C4/W1 still grew up to high viral titers (9.0 log10 EID50/
ml), while the low-temperature passaged virus was highly
impaired in growth (under limited detection). TheseFigure 1 Temperature-sensitive phenotype of the recombinant
viruses. Six 10-day-old embryonated SPF chicken eggs were
inoculated with 103 EID50 (0.2 ml/egg) of the recombinant viruses
and incubated at 37°C and 41°C for 48 hours. Viral titers were
determined by log10EID50/ml at 37°C. The detection limit is
0.7 log10EID50/ml. The statistical analysis was performed using
Student’s t test (★★, p< 0.01; ★, p< 0.05).results indicated that the low-temperature passaged virus
acquired ts phenotype and was named ts-C4/W1.
Subsequently, eight gene segments of the virus ts-C4/W1
were sequenced and compared with that of virus C4/W1. Fiveaminoacidmutationswereidentifiedinthegenomeofthevirusts-C4/W1.TheywerePB1(K698N),PA(F35S),HA(H119Y),M1(R174K)andNS1(K108N)(datanotshown).Todeterminewhichaminoacidmutationormutationscontributedtothetsphenotypeofthevirusts-C4/W1,thefiveaminoacidmutationswereindividuallyintroducedintovirusC4/W1andfivesingle-mutatio recombinantvirusesweregenerated.Thetsphenotypeof thesesingle-mutationrecombinantviruseswasevaluated.AsshowninFigure1,four ofthefivesingle-mutationrecombinantvirusesincludingC4/W1-PB1(K698N),C4/W1 HA(H119Y),C4/W1-M1(R174K)andC4/W1-NS1(K108N)didnotdisplaytsphenoty e,theygrewup tosimilar itersat37°Cor 41°C.Therestsingle-mutationrecombinantvirusC4/W1-PA(F35S)grewefficientlyat°C( 8.9log10EID50/ml)inc hickeneggs,butwashighlyimpaired ingrowthat41°C(underlimiteddetection).TheseresultsindicatedthatPA (F35S)wasthets mut tion.
To determine whether recombinant virus with the ts
mutation PA (F35S) was attenuated in chickens, patho-
genicity and growth property of the single-mutation re-
combinant virus C4/W1-PA (F35S) was assessed, viruses
ts-C4/W1 and C4/W1 were used as comparison. Animal
studies were performed according to protocols approved
by the Hubei Provincial Animal Care and Use Commit-
tee. The intravenous pathogenicity index (IVPI) was per-
formed [15] and indicated that virus C4/W1-PA (F35S)
(IVPI = 0) as well as virus ts-C4/W1 (IVPI = 0) was more
attenuated than virus C4/W1 (IVPI = 0.8). To assess
growth property, groups of 3-week-old White Leghorn
chickens were inoculated intranasally (i.n.) with 0.2 ml
106 EID50 of the single-mutation recombinant virus C4/
W1-PA (F35S), ts-C4/W1 or C4/W1, At 3 and 5 days
post-inoculation (p.i.), four chickens in each group were
sacrificed, tracheal swabs, cloacal swabs and lungs were
collected in 1 ml phosphate buffered saline (PBS) con-
taining penicillin and streptomycin, lungs were homoge-
nized. Viral titers were determined by EID50 at 37°C.
Virus C4/W1 grew efficiently in chickens and could be
detected in tracheal swabs, cloacal swabs and lungs of
inoculated chickens with high viral titers at 3 and 5 days
p.i.; virus ts-C4/W1 couldn’t be detected in any swabs or
lungs of the inoculated chickens; while virus C4/W1-PA
(F35S) could only be detected in the tracheal swabs of
inoculated chickens at 3 days p.i. with much less viral
titers (1.8 log10EID50/ml) (Table 1). All these data
showed that the single-mutation recombinant virus C4/
W1-PA (F35S) as well as virus ts-C4/W1 was non-
pathogenic to chickens and highly impaired in growth in
chickens, which was critically important as LAIV.
In addition, live attenuated vaccine must be non-
pathogenic to vaccine operators before used in poultry.
Here, mice were used to assess the virulence of virus C4/
W1-PA (F35S). The fifty percent mouse lethal dose
(MLD50) was determined as described previously [15].
As shown in Table 1, virus C4/W1-PA (F35S) and virus ts-
C4/W1 were more attenuated (MLD50> 8.0 log10EID50/
50 μl) in mice than virus C4/W1 (MLD50=6.5 log10EID50/
50 μl). This phenotype of attenuation could also be
observed from body weight loss of mice infected i.n. with
50 μl 106 EID50 of virus C4/W1-PA (F35S), ts-C4/W1 or
C4/W1. Virus C4/W1 caused maximum 20% of initial body
weight loss, while no apparent body weight loss was
observed when mice infected with virus C4/W1-PA (F35S)
or ts-C4/W1 (Data not shown). Their growth ability in
mice was also determined. Groups of 6-week-old female
BALB/c mice were inoculated i.n. with 50 μl 106 EID50
of virus C4/W1-PA (F35S), ts-C4/W1 or C4/W1. At
Table 1 Pathogenicity and growth property of recombinant viruses in chickens and mice
Viruses IVPI Virus replication in chickens# (log10EID50/ml ± SE) MLD50(log10EID50/50 μl) Virus replication in mice
&
(log10EID50/ml ± SE)Day 3 Day 5
Trachea Cloacal Lungs Trachea Cloacal Lungs Day 3 Day 6
C4/W1 0.8 4/4* (3.9 ± 0.4) 4/4 (2.4 ± 0.5) 4/4 (3.5 ± 0.2) 4/4 (5.4 ± 0.2) 3/4 (3.3 ± 0.3) 4/4 (4.7 ± 0.6) 6.5 3/3* (4.6 ± 0.2) 3/3 (3.3 ± 0.3)
ts-C4/W1 0 0/4 0/4 0/4 0/4 0/4 0/4 >8.0 2/3 (1.6 ± 0.1) 0/3
C4/W1-PA(F35S) 0 4/4 (1.8 ± 0.3) 0/4 0/4 0/4 0/4 0/4 >8.0 3/3 (3.4 ± 0.3) 2/3 (2.5 ± 0.1)
Note: IVPI, intravenous pathogenicity index; MLD50, 50% mouse lethal dose; EID50, 50% egg infectious dose; SE, standard errors.
# Groups of chickens were inoculated intranasally with 0.2 ml 106 EID50 of the indicated viruses. At 3 and 5 days post-inoculation, viral titers in tracheal swabs, cloacal swabs and lungs were determined by testing their
EID50 at 37°C, values are the means ± standard errors.
&Groups of mice were inoculated intranasally with 50 μl 106 EID50 of the indicated viruses. At 3 and 6 days post-inoculation, viral titers in lungs were determined by testing their EID50 at 37°C, values are the
means ± standard errors.














Table 2 Protective efficacy of the live attenuated H5N1 influenza vaccine in chickens
Vaccine groups# Challenging
virus
Positive/total No. (HI antibody, log2)
before challenge
Death rate Shedding/total (log10EID50/ml ± SE)
trachea cloacal
ts-C4/W1 C4 0/6 6/6$ ND (dead&) ND (dead)
D6 0/6 6/6 ND (dead) ND (dead)
C4/W1-PA(F35S) C4 6/6* (2.3) 0/6 0/6 0/6
D6 5/6 (2.6) 0/6 0/6 0/6
PBS C4 0/6 6/6 ND (dead) ND (dead)
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http://www.virologyj.com/content/9/1/97days 3 and 6 p.i., three mice in each group were sacri-
ficed, and lungs were removed and homogenized in 1 ml
PBS containing penicillin and streptomycin. Viral titers
were determined by EID50 at 37°C. The results showed
that viruses C4/W1-PA (F35S) and ts-C4/W1 grew up to
lower titers than that of virus C4/W1 at 3 or 6 days p.i.
(Table 1).
The PA subunit was reported to be critical in modulat-
ing ribonucleoprotein (RNP) activity under thermal
stress (Kashiwagi et al., 2010) [18]. Effects of the ts mu-
tation PA (F35S) on polymerase activity was analyzed at
different temperatures (37°C and 41°C) using minige-
nome reconstitution assay as described previously (Sun
et al., 2010) [19]. The RNP components of virus C4/W1
and C4/W1-PA(F35S) showed similar Luciferase activ-
ity at 37°C. However, at 41°C, the Luciferase activity of
the RNP components of virus C4/W1 was 5.3-fold that
of virus C4/W1-PA(F35S) (data not shown). The position
35 was near the endonuclease active site 41 of PA (Yuan
et al., 2009) [20], whether the amino acid mutation PA
(F35S) restricted the endonuclease activity of PA to some
extent under thermal stress needed to be identified.
To determine the protective efficacy of the indicated
vaccines in chickens, groups of twelve 3-week-old White
Leghorn chickens were inoculated i.n. with 0.2 ml 106
EID50 of the virus C4/W1-PA (F35S), ts-C4/W1 or
0.2 ml PBS. Three weeks post-vaccination, six chickens
in each group were challenged with 100 50% chicken le-
thal dose (CLD50) of either virus C4 (clade 9) or virus A/
Duck/Hubei/hangmei01/2006 (H5N1) (D6) (clade 2.3.4)
(Zou et al., 2009) [21], tracheal and cloacal swabs were
collected at days 3 post-challenge (p.c.) for virus titration
and chickens were observed for death and disease signs
for two weeks. As shown in Table 2, virus C4/W1-PA
(F35S) induced detectable HI antibody titers and can pro-
vide efficient protection against the same clade or cross-
clade H5N1 HPAIV with undetectable viral titers from
tracheal or cloacal swabs at 3 days p.c., while all the
chickens received with virus ts-C4/W1 or PBS died.
Different sublineages of avian H9N2 influenza virus
showed different pathogenicity to chickens or mice.
Virus of A/Quail/Hong Kong/G1/97 sublineage with in-
ternal genes similar to the highly pathogenic Hong
Kong/97 H5N1 influenza virus killed mice and spread to
mouse brain, while virus of A/Duck/Hong Kong/Y280/
97 H9N2 (Y280) sublineage were nonpathogenic to
chickens or mice (Guo et al., 2000) [22]. Choosing a
nonpathogenic H9N2 influenza virus as backbone might
be safer and the stain W1 used in this study as avian
backbone was the Y280-sublineage.
In light of rare LAIV used for poultry, we highlighted
the potential of the new and simple ts mutation PA
(F35S) in developing recombinant avian H5N1 LAIV
with avian H9N2 influenza virus as backbone.Competing interests
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